DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Creative Planning

Creative Planning lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 22.3% during the third quarter, Holdings Channel reports. The fund owned 59,573 shares of the medical device company’s stock after purchasing an additional 10,880 shares during the quarter. Creative Planning’s holdings in DexCom were worth $3,994,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the 2nd quarter worth about $25,000. Sachetta LLC grew its holdings in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. Crewe Advisors LLC purchased a new stake in shares of DexCom during the 1st quarter worth about $29,000. DT Investment Partners LLC grew its holdings in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the period. Finally, RiverPark Advisors LLC purchased a new stake in shares of DexCom during the 1st quarter worth about $55,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. Barclays reduced their price target on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Royal Bank of Canada reduced their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 target price on shares of DexCom in a research report on Tuesday, July 23rd. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Baird R W lowered DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Six analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Performance

Shares of DXCM opened at $73.44 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The stock has a 50-day moving average price of $70.11 and a 200-day moving average price of $98.24. The company has a market cap of $29.21 billion, a PE ratio of 47.38, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 24th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. The firm had revenue of $994.20 million for the quarter, compared to analysts’ expectations of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. As a group, equities analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,824 shares of company stock valued at $126,390. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.